RecruitingNCT00710177
PTGS1 Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn
Prostaglandin G/H Synthase-1 (PTGS1) Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn (PPHN)
Sponsor
Medical College of Wisconsin
Enrollment
200 participants
Start Date
Jan 1, 2006
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to determine if normally occurring variations in a specific gene called PTGS-1 are associated with an increased risk of narrowing of the ductus arteriosus from exposure to over-the-counter pain medicines (NSAIDs).
Eligibility
Max Age: 12 Months
Inclusion Criteria1
- Infants born greater than or equal to 34 weeks gestational age diagnosed with PPHN and normal, healthy infants born greater than or equal to 34 weeks gestational age.
Exclusion Criteria4
- Patients will be excluded if they are diagnosed with lethal congenital anomalies
- structural congenital heart disease except presence of patent ductus arteriosus (PDA) or patent foramen ovale
- structural gastrointestinal tract abnormality that could interfere with meconium passage
- congenital anomalies such as diaphragmatic hernia, Potter's syndrome, or pulmonary hypoplasia
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT00710177